Tango Therapeutics, Inc. (TNGX)
NASDAQ (NMS) NASDAQ (NMS) Primary 
TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data
Tango Therapeutics stock falls 16.4% despite an 82% pancreatic cancer response rate and durable disease control, as investors weigh updated results and R&D cuts.
Tango Therapeutics, Inc. (TNGX) Discusses Updated Vopimetastat Combination Data and Registration Strategy in Pancreatic Cancer Transcript
Tango Therapeutics, Inc. (TNGX) Discusses Updated Vopimetastat Combination Data and Registration Strategy in Pancreatic Cancer Transcript
Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response Rate
Tango Therapeutics NASDAQ: TNGX said it plans to begin a global Phase III trial in the first half of 2027 evaluating vopimetostat in combination with daraxonrasib as a first-line treatment for patients with MTAP-deleted metastatic pancreatic ductal adenocarcinoma, or PDAC.
Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?
Tango Therapeutics (TNGX) reported earnings 30 days ago. What's next for the stock?
Tango Therapeutics: Promising Early Data, But A Long Road Ahead
Vopimetostat's combination with daraxonrasib has produced an unusually strong early pancreatic-cancer signal, but the evidence still comes from a very small, previously treated cohort. A planned front-line Phase 3 trial could substantially expand the opportunity, although its final design, timing, and regulatory path remain unsettled. Additional combination, lung-cancer, and CNS readouts should show whether TNGX is building a broader PRMT5 franchise or relying too heavily on one early dataset.
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses
Tango Therapeutics stock falls 5% on a wider-than-expected Q2 loss, reflecting higher operating expenses, while pipeline progress remains in focus.
How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48%
The average of price targets set by Wall Street analysts indicates a potential upside of 49.5% in Tango Therapeutics (TNGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?
Tango Therapeutics' strong 2026 rally reflects promising clinical progress, but its premium valuation puts upcoming study results at the center of the next move.
Tango Therapeutics Rides a New Precision Oncology Trend in 2026
TNGX is advancing precision oncology with MTAP-targeted therapies and 2026 data readouts that could test its clinical and commercial potential.
TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalysts
Tango Therapeutics enters a pivotal phase as vopimetostat drives its investment case, with 2026 clinical updates set to test its focused oncology pipeline.
TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results
Tango Therapeutics rises 53% after early pancreatic cancer study data show strong response rates for vopimetostat combinations and support late-stage plans.
Tango Therapeutics, Inc. (TNGX) Discusses Promising Clinical Results for Vopimetostat and Pan-RAS Inhibitor Combination in MTAP-Deleted Pancreatic Cancer Transcript
Tango Therapeutics, Inc. (TNGX) Discusses Promising Clinical Results for Vopimetostat and Pan-RAS Inhibitor Combination in MTAP-Deleted Pancreatic Cancer Transcript
